HIC
NVS icon

Hamrick Investment Counsel’s Novartis NVS Stock Holding History

Hamrick Investment Counsel’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.7K Hold
100
– – 0.01% 127
2026
Q1 		$15.3K Hold
100
– – 0.01% 216
2025
Q4 		$13.8K Buy
+100
New +$13.1K 0.01% 126

Other funds holding NVS

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Hamrick Investment Counsel's NVS Position: Q2 2026 in Review

Hamrick Investment Counsel held its Novartis (NVS) position steady in Q2 2026 at 100 shares worth $15.7K. The position accounts for 0.01% of the portfolio, ranked #127.

Hamrick Investment Counsel first reported a position in NVS in Q4 2025 and has held it in 3 quarters since. 1,625 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Hamrick Investment Counsel held 100 shares of Novartis worth $15.7K as of Q2 2026.
  • Hamrick Investment Counsel left its Novartis share count unchanged in Q2 2026.
  • Novartis made up 0.01% of Hamrick Investment Counsel's portfolio in Q2 2026, its #127 holding.
  • Hamrick Investment Counsel first reported a position in Novartis in Q4 2025 and has held it in 3 quarters since.
  • 1,625 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Hamrick Investment Counsel's 13F filing for Q2 2026, filed 13 Aug 2026.